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Abstract
Background: Prevalence of bacteremia caused by non-fermentative gram-negative bacteria (NFGNB) has been
increasing over the past decade. Although many studies have already investigated epidemiology of NFGNB
bacteremia, most focused only on common NFGNB including Pseudomonas aeruginosa (PA) and Acinetobacter
baumannii (AB). Knowledge of uncommon NFGNB bacteremia is very limited. Our study aimed to investigate
epidemiology and identify factors associated with uncommon NFGNB bacteremia.
Methods: This observational study was conducted at a university hospital in Thailand during July 1, 2007-Dec 31,
2008. All patients who had at least one blood culture positive for NFGNB and met the criteria for systemic
inflammatory response syndrome within 24 hours before/after obtaining the blood culture were enrolled. The
NFGNB isolates that could not be satisfactorily identified by the standard biochemical assays were further
characterized by molecular sequencing methods. To identify factors associated with uncommon NFGNB bacteremia,
characteristics of patients in the uncommon NFGNB group were subsequently compared to patients in the
common NFGNB group (AB and PA bacteremia).
Results: Our study detected 223 clinical isolates of NFGNB in 221 unique patients. The major causative pathogens
were AB (32.7%), followed by PA (27.8%), Stenotrophomonas maltophilia (5.4%), Acinetobacter lwoffii (4.9%) and
Burkholderia pseudomallei (2.7%). Infection-related mortality was 63.0% in the AB group, 40.3% in the PA group and
17.4% in the uncommon NFGNB group. Factors associated with uncommon NFGNB bacteremia (OR [95% CI];
p-value) were male sex (0.28 [0.14-0.53]; p < 0.001), hospital-acquired infection (0.23 [0.11-0.51]; p < 0.001), recent
aminoglycosides exposure 0.23 [0.06-0.8]; p = 0.01), primary bacteremia (6.43 [2.89-14.2]; p < 0.001]), catheter related
infection (4.48 [1.54-13.06]; p < 0.001) and recent vancomycin exposure (3.88 [1.35-11.1]; p = 0.02).
Conclusions: Our distribution of causative pathogens was slightly different from other studies. The common
NFGNB group had a remarkably higher ID-mortality than the uncommon NFGNB group. Knowledge of factors
associated with uncommon NFGNB bacteremia would help physicians to distinguish between low vs. high risk
patients.
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Background
Bacteremia is a serious infection which is associated with
high morbidity and mortality [1]. Gram-negative bacteria
have been documented as the most common cause of
bacteremia in many countries including Thailand [2-4].
Infections caused by non-fermentative gram-negative
bacteria (NFGNB) constitute an emerging problem in
nosocomial setting, especially in an immunocomprom-
ised host. NFGNB are very problematic because of their
ubiquitous distributions in the environment and their
antimicrobial resistance patterns [5]. Data from the Sur-
veillance and Control of Pathogens of Epidemiological
importance (SCOPE) study revealed that approximately
one-fourth of gram-negative bacteremia attributed to
NFGNB [4].
Among all NFGNB, Pseudomonas aeruginosa and
Acinetobacter baumannii are the most common causa-
tive pathogens for bacteremia [4,6,7]. Other uncommon
NFGNB comprise many species such as Stenotrophomonas
maltophilia, Burkholderia spp., Alcaligenes spp., Ralstonia
spp., Sphingobacterium spp., etc. [8]. Although many
studies have investigated epidemiology of bacteremia
caused by NFGNB, most studies focused only on P.
aeruginosa and A. baumannii [4,9-11]. Knowledge of
bacteremia caused by uncommon NFGNB is very lim-
ited. Lack of data on the disease epidemiology is a great
obstacle to improve quality of care. Given these consid-
erations, we conducted an observational study to explore




This study was conducted at Siriraj hospital, a 2200-bed,
tertiary-care university hospital in Bangkok, Thailand.
The study protocol including waiver of informed con-
sent for using patients' clinical isolates were approved by
Siriraj Institutional Review board. From July 1, 2007 -
December 31, 2008, all patients in whom at least one
blood culture positive for NFGNB were prospectively
identified through the microbiology laboratory database.
Only patients who met the criteria of systemic inflam-
matory response syndrome (SIRS) within 24 hours be-
fore or after obtaining blood culture were enrolled in the
study. If NFGNB were isolated on multiple occasions
from the same patient, only the first episode of bacteremia
was included.
Microbiologic procedures and isolate identification
Microbiological and susceptibility results of all patients
were retrieved from the microbiology laboratory data-
base. All blood cultures during the study period were
processed by the BactT/ALERT system (bioMeriéux)
according to manufacturer’s protocol. Identification to
the species level was achieved by using the Vitek 2 and/
or API 20NE systems (bioMeriéux). All clinical isolates
that could not be satisfactorily identified by the Vitek 2
or API 20NE were further characterized by 16S rDNA
sequencing. Approximately 800 bp at the 5’ terminal of
16S rDNA gene was PCR amplified and sequenced using
primers and protocols as described elsewhere [12,13].
The sequencing results were compared with databases in
the GenBank (the nucleotide-nucleotide Basic Local
Alignment Search Tool or BLAST).
Susceptibility testing was performed by Disk Diffusion
or Broth Microdilution method as appropriate. Suscepti-
bilities to each antimicrobial agent were determined
according to criteria established by the Clinical and La-
boratory Standards Institute [14,15]. Since the Clinical
and Laboratory Standards Institute (CLSI) criteria for
polymyxin E and tigecycline are not available, suscepti-
bilities to tigecycline and polymyxin E were interpreted
by using the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) clinical breakpoints
[16]. We could not report the susceptibility results of
some NFGNB species because the standard interpret-
ation method is not available. Names of antimicrobial
agent were abbreviated as follows: ceftazidime (CAZ),
cefipime (FEP), ciprofloxacin (CIP), colistin or poly-
myxin E (CST), gentamycin (GEN), cotrimoxazole (SXT),
imipenem-cilastatin (IMP), piperacillin-tazobactam (TZP)
and tigecycline (TIG).
Data collection
Medical records were retrospectively reviewed to obtain data
including age, sex, hospital service, previous hospitalization,
comorbidities, presence of a central venous catheter at the
onset of infection, use of antimicrobial therapy or immuno-
suppressive agents in the preceding 30 days, suspected
source(s) of bacteremia and infection-related mortality
within 28 days after the onset of bacteremia (ID-mortality).
The presence of the following comorbidities at the time
of bacteremia was documented: cardiovascular diseases,
chronic renal diseases, chronic liver diseases, chronic
lung diseases, diabetes mellitus, neurological diseases,
hematologic malignancy, solid cancer, HIV infection and re-
ceiving immunosuppressive therapy. We also recorded a
number of blood cultures obtained, a number of positive
blood cultures, other pathogens identified in the same set of
blood cultures and hospital days both before and after the
onset of bacteremia. We considered the date of obtaining
the first positive blood culture as the onset of bacteremia.
Definitions
Pseudomonas aeruginosa and Acinetobacter baumannii
were considered the common NFGNB while all other
NFGNB pathogens were considered the uncommon
NFGNB.
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Multidrug resistance was defined as resistance to
carbapenems, second and third generation-cephalosporins,
anti-pseudomonas penicillins, fluoroquinolones and
aminoglycosides.
A bacteremic episode was considered to be hospital-
acquired if one of the following criteria was true; 1) it
occurred at least 48 hours after the admission and did
not present or incubate at the time of admission; 2) it
presented on the admission but the patient had been
transferred from another medical center or long-term
care facility, had spent at least 48 hours in the given fa-
cility; or 3) it presented on the admission but the patient
has been hospitalized within the past 2 weeks [17].
A site of infection was determined by using the CDC
definitions of nosocomial infections [17]. The site of in-
fection was considered a suspected source of bacteremia
if a similar NFGNB had also been isolated from that site
within 24 hours before or after the onset of bacteremia.
Therefore, each patient may have more than one
suspected sources of bacteremia.
Receiving immunosuppressive agents was documented
if the patient had a history of corticosteroid use (receipt
of prednisone at a dosage of 20 mg per day (or equiva-
lent) for at least 2 weeks) and/or history of receipt of
chemotherapeutic agents in the preceding 30 days.
ID-mortality was defined as death in the setting of
clinical evidence of active infection (elevated WBC and
or elevated body temperature) and death within 5 days
of last positive culture result.
Statistical analysis
Descriptive statistics were used to express overall results.
Univariate analysis was performed to determine an un-
adjusted association between the uncommon NFGNB
bacteremia and other variables. Categorical variables were
compared by using chi-square or Fisher’s exact test while
continuous variables were compared by using t-test or
Wilcoxon rank sum test as appropriate. To identify factors
that independently associated with the uncommon
NFGNB bacteremia, we subsequently built a multivariate
logistic model by the stepwise method which is a combin-
ation of backward elimination and forward selection
approaches. Variables were included in the multivariable
model if they presented a p-value ≤0.20 in univariate ana-
lysis and then removed from the final multivariable model
if they did not exhibit an adjusted p-value <0.05. A 2-
tailed p-value of <0.05 was considered significant. All
statistical calculations were performed by using STATA,
version 12 (Stata Corp, College Station, TX).
Results
Distribution of causative pathogens
During the study period, there were a total of 221 pa-
tients with NFGNB bacteremia. Two patients (0.9%) had
Table 1 Distribution of causative pathogens
Causative pathogen Number of clinical
isolates (%), n = 223
1. Pathogens identified by biochemical-
based methods
153 (68.6)
Acinetobacter baumannii 73 (32.7)
Pseudomonas aeruginosa 62 (27.8)
Stenotrophomonas maltophilia 12 (5.3)
Burkholderia pseudomallei 6 (2.7)
2. Pathogens identified by 16S rDNA
sequencing
51 (22.9)
Acinetobacter spp. (other than A. baumannii) 11 (4.9)
▪ Acinetobacter lwoffii 10 (4.5)
▪ Acinetobacter spp. (unidentified species) 1 (0.4)
Pseudomonas spp. (other than P. aeruginosa) 12 (5.4)
▪ Pseudomonas putida 6 (2.7)
▪ Pseudomonas stutzeri 5 (2.2)
▪ Pseudomonas spp. 1 (0.4)
Burkholderia spp. (other than B. pseudomallei) 6 (2.7)
▪ Burkholderia cepacia 4 (1.8)
▪ Burkholderia mallei 1 (0.4)
▪ Burkholderia spp. 1 (0.4)
Ralstonia spp. 6 (2.7)
▪ Ralstonia mannitolilytica 2 (0.9)
▪ Ralstonia pickettii 1 (0.4)
▪ Ralstonia spp. 3 (0.9)
Elizabethkingia meningoseptica 2 (0.9)
Chryseobacterium spp. 2 (0.9)
▪ Chryseobacterium menigosepticum 1 (0.4)
▪ Chryseobacterium spp 1 (0.4)
Acrobacter xylosoxidans 2 (0.9)
Aeromonas veronii biovar sobria 1 (0.4)
Agrobacterium spp. 1 (0.4)
Cupriavidus pauculus 1 (0.4)
Halomonas spp. 1 (0.4)
Herbassirillum huttiense 1 (0.4)
Roseomonas massiliae 1 (0.4)
Shewanella putrefaciens 1 (0.4)
Sphingomonas spp. 1 (0.4)
Wautersiella falsenii 1 (0.4)
Xanthomonas campestris 1 (0.4)
3. Isolates that could not be identified by 16S
rDNA sequencing*
11 (4.9)
4. Insufficient specimens** 8 (3.6)
Note. * The sequence of these isolates did not match our sequence database.
** Amount of these isolates was not enough for the molecular study.
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blood cultures positive for two species of NFGNB in a
same set. The first patient had bacteremia caused by
Chryseobacterium meningosepticum and Elizabethkingia
meningoseptica. The second patient had bacteremia
caused by Ralstonia spp. and Burkholderia mallei.
Therefore, we detected 223 clinical isolates of NFGNB
in 221 unique patients. In addition to a NFGNB patho-
gen, 25 patients (11.3%) also had a blood culture positive
for a non-NFGNB pathogen, including Escherichia coli
(n = 7), Klebsiella pneumoniae (n = 5), Enterobacter spp.
(n = 3), Enterococcus faecalis (n = 2), Staphylococcus
aureus (n = 2), alpha-hemolytic streptococci (n = 1) and
fungi (n = 5). The most common combination was P.
aeruginosa and E. coli (n = 7), followed by P. aeruginosa
and K. pneumoniae (n = 5).
Approximately one-third of all clinical isolates (70/
223) could not be identified by the standard biochemical
methods. Of these 70 isolates, we could not perform the
molecular study in 8 isolates due to an insufficient
amount of specimens and we could not match the se-
quence of 11 isolates with our sequence database. A
total of 51 isolates were successfully identified by the
molecular method. The major causative pathogens were
Acinetobacter baumannii (32.7%), followed by Pseudo-
monas aeruginosa (27.8%), Stenotrophomonas maltophilia
(5.4%), Acinetobacter lwoffii (4.9%) and Burkholderia
pseudomallei (2.7%). Distribution of causative pathogens
and list of pathogen identified by the 16S rDNA sequen-
cing are shown in Table 1.
Susceptibility patterns
Details of antimicrobial susceptibility are shown in Table 2.
Prevalence of multi-drug resistance (MDR) was 68.5% in
A. baumannii and 5.1% in P. aeruginosa. Of the MDR
isolates, CST was active against 87.2% of A. baumannii
and 80% of P. aeruginosa. Less than 1/3 of A. baumannii
isolates were susceptible to TIG. Despite the CST and
TIG, the most active antibiotic was GEN (28.2%) for A.
baumannii, TZP (91.5%) for P. aeruginosa and SXT
(80.0%) for S. maltophilia. All of B. pseudomallei isolates
(100.0%) were susceptible to CAZ and IMP while only
75% susceptible to SXT.
Clinical characteristics
Detail of baseline characteristics, comorbidities and clinical
features are shown in Table 3. Based on data from 221
unique patients, the median age [interquartile range] of our
study subjects was 54 years [37–71] while the median
length of hospital stay prior to the onset of bacteremia was
6 days [0–17]. Of these 221 patients, 116 (52.5%) were male
and 167 (75.5%) had hospital-acquired bacteremia. Ap-
proximately 17% (9/54) of community-acquired bacteremia
and 11% (18/167) of hospital-acquired bacteremia were
polymicrobial. The three leading sources of bacteremia
were pneumonia (34.4%), primary bacteremia (22.1%) and
gastrointestinal tract (11.3%).
Antimicrobial therapy
Due to a very high prevalence of multi-drug resistant
pathogens, only half of patients (50.7%, 112/221) re-
ceived at least one antimicrobial agent that active against
causative pathogen(s) on the onset date. Percent of patients
who received adequate antimicrobial therapy on the onset
date was 66.1% in P. aeruginosa, 31.5% in A. baumannii,
16.7% in S. maltophilia, 100% in B. pseudomallei and
58.8% among the rest.
Clinical outcomes
The ID-mortality was 38.9% (86/221) in all study sub-
jects, 52.5% (71/135) in the common NFGNB group
and 17.4% (15/86) in the uncommon NFGNB group.
The ID-mortality was highest among patients with A.
Table 2 Antimicrobial susceptibilities
Antimicrobial agents % Susceptible (number of susceptible isolates/number of tested isolates)
A. baumannii P. aeruginosa S. maltophilia B. pseudomallei
Ceftazidime 22.9 (16/70) 80.4 (45/56) 40.0 (2/5) 100.0 (6/6)
Cefepime 20.8 (15/72) 74.1 (40/54) - -
Piperacillin/tazobactam 20.6 (15/73) 91.5 (54/59) - -
Ciprofloxacin 18.6 (13/70) 75.4 (43/57) - -
Gentamycin 28.2 (20/71) 79.3 (46/58) - -
Imipenem/cilastatin 23.3 (17/73) 89.7 (52/58) - 100.0 (6/6)
Cotrimoxazole 30.0 (21/70) - 80.0 (8/10) 75.0 (45/60)
Multi-drug resistance* 68.5 (50/73) 5.1 (3/59) - -
Polymyxin E ** 87.2 (41/47) 80.0 (4/5) - -
Tigecycline** 31.3 (10/32) - - -
*% Resistant (number of resistant isolates/number of tested isolates).
** Polymyxin E and tigecycline were only tested against some multi-drug resistant isolates.
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Table 3 Baseline characteristics, comorbidities and clinical features of patients in the uncommon NFGNB group vs. the
common NFGNB group
Variables Uncommon NFGNB Common NFGNB Unadjusted OR P-value
(N = 86) (N = 135) [95% CI]
Median age (interquartile range), years 55 (37–70) 54 (37–71) 0.996 [0.984-1.007] 0.44
Median length of stay prior to bacteremia onset (interquartile range), days 1.5 (0–12) 10 (2–20) 0.996 [0.986-1.005] 0.37
Male sex 30 (34.9%) 86 (63.7%) 0.31 [0.17-0.56] <0.001
Services
▪ Medicine 49 (57.0%) 81 (60.0%) 0.54 [0.26-1.13] 0.13
▪ Surgery 17 (19.8%) 36 (26.7%) 0.43 [0.18-1.00]
▪ Others 20 (23.2%) 18 (13.3%) Reference group
Underlying diseases
▪ Hematologic malignancies 11 (12.8%) 38 (28.2%) 0.37 [0.16-0.81] 0.007
▪ Cardiovascular diseases 44 (51.2%) 45 (33.3%) 2.10 [1.16-3.78] 0.008
▪ Chronic renal diseases 18 (20.9%) 17 (12.6%) 1.83 [0.83-4.06] 0.10
▪ Chronic liver diseases 7 (8.1%) 9 (6.7%) 1.24 [0.38-3.91] 0.68
▪ Chronic lung diseases 4 (4.7%) 9 (6.7%) 0.68 [0.15-2.55] 0.77*
▪ Solid tumor 21 (24.4%) 27 (20.0%) 1.29 [0.64-2.59] 0.44
▪ Diabetes 23 (26.7%) 26 (19.3%) 1.53 [0.76-3.05] 0.19
▪ HIV infection 1 (1.2%) 1 (0.7%) 1.58 [0.20-124.65] 0.99*
▪ Receiving immunosuppressive agents 6 (7.0%) 5 (3.7%) 1.95 [0.48-8.33] 0.28
▪ Neurological diseases 2 (2.3) 6 (4.4%) 0.51 [0.05-2.96] 0.49*
Recent antibiotic exposure within 30 d
▪ All antibiotics 44 (51.2%) 95 (70.4%) 0.44 [0.24-0.80] 0.004
▪ Beta-lactams 40 (46.5%) 88 (65.2%) 0.46 [0.26-0.84] 0.006
▪ Cephalosporins 22 (25.6%) 53 (39.3%) 0.53 [0.28-1.00] 0.04
▪ Carbapenems 13 (15.1%) 21 (15.6%) 0.97 [0.42-2.17] 0.93
▪ Beta-lactam/beta-lactamase inhibitors 10 (11.6%) 24 (17.8%) 0.61 [0.25-1.42] 0.22
▪ Fluoroquinolones 9 (10.5%) 12 (8.9%) 1.20 [0.42-3.26] 0.70
▪ Aminoglycosides 5 (5.8%) 25 (18.5%) 0.27 [0.08-0.77] 0.007
▪Polymyxin E 3 (3.5%) 1 (0.7%) 4.84 [0.38-256.08] 0.30*
▪ Vancomycin 13 (15.1%) 12 (8.9%) 1.83 [0.72-4.62] 0.15
▪ Metronidazole 1 (1.2%) 15 (11.1%) 0.09 [0.002-0.64] 0.006*
▪ Cotrimoxazole 0 6 (4.4%) . . .. 0.84*
▪ Clindamycin 3 (3.5%) 9 (6.7%) 0.51 [0.09-2.11] 0.38*
Clinical characteristics
Hospital-acquired infection 55 (64.0%) 112 (83.0%) 0.36 [0.18-0.72] <0.001
Sites of infection
• Primary bacteremia 31 (36.1%) 18 (13.3%) 3.66 [1.79-7.56] <0.001
• Pneumonia 24 (27.9%) 52 (38.5%) 0.62 [0.33-1.15] 0.11
• Urinary tract 5 (5.8%) 15 (11.1%) 0.49 [0.14-1.51] 0.18
• Gastrointestinal tract 8 (9.3%) 17 (12.6%) 0.72 [0.25-1.85] 0.45
• Catheter-related infection 12 (13.9%) 9 (6.7%) 2.27 [0.83-6.39] 0.07
• Soft tissue and surgical site infection 0 7 (5.2%) . . .. 0.05*
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baumannii bacteremia (63.0%, 46/73), followed P.
aeruginosa bacteremia (40.3%, 25/52). There was no
significant difference in the ID-mortality between those
with monomicrobial bacteremia vs. polymicrobial bac-
teremia (39.7% vs. 33.3%; p = 0.53). Details of the ID-
mortality across the causative pathogens are shown in
Figure 1.
Factors associated with uncommon NFGNB bacteremia
To identify factors associated with bacteremia caused by
uncommon NFGNB, we subsequently compared charac-
teristics of patients with uncommon NFGNB bacteremia
(S. maltophilia, B. pseudomallei and all other uncom-
mon NFGNB species) to patients with common NFGNB
bacteremia (P. aeruginosa and A. baumannii). When base-
line characteristics of patients in both groups were
compared, a median length of hospital stay prior to the
onset of bacteremia was slightly lower in the uncommon
NFGNB group (1.5 day vs. 10 days). However, this
difference did not reach statistical significance. Patients in
the uncommon NFGNB group were less likely to have
underlying hematologic malignancy as well as expo-
sure to beta-lactams, aminoglycosides and metronidazole.
However, the uncommon NFGNB group had a higher
prevalence of underlying cardiovascular diseases.
The factors that were found to be independently asso-
ciated with the uncommon NFGNB bacteremia are
presented in Table 4. The independently associated fac-
tors included having primary bacteremia or catheter re-
lated blood stream infection as a source of bacteremia
and previous exposure to vancomycin. Additionally,
male sex, hospital-acquired infection and previous ex-
posure to aminoglycoside were identified as protective
factors in the multivariable model.
Discussion
Our three leading causative pathogens were A. baumannii,
followed by P. aeruginosa and S. maltophilia. These path-
ogens are commonly known as opportunists especially in
the hospital setting. They are distributed ubiquitously in
diverse environmental sources such as tap water or con-
taminated solutions [5]. Our distribution of causative
pathogens was slightly different from previous studies that
were conducted in the southern part of Thailand, US and
Europe. All of these studies found that the three leading
causative pathogens were P. aeruginosa, followed by A.
baumannii and S. maltophilia [7,18-20]. We hypothesize
Table 3 Baseline characteristics, comorbidities and clinical features of patients in the uncommon NFGNB group vs. the
common NFGNB group (Continued)
• Febrile neutropenia 4 (4.7%) 15 (11.1%) 0.39 [0.09-1.29] 0.14*
• Others 1 (1.2%) 1 (0.7%) 1.58 [0.20-124.65] 0.99*
Infection-related mortality 15 (17.4%) 71 (52.6%) 0.19 [0.09-0.38] <0.001


















































Figure 1 Number of total patients and patients who died due to infection (represented as a bar graph) and percent of ID-mortality
(represented as a bar graph), classified by the causative pathogens.
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that the remarkably high prevalence of A. baumannii may
be the result of clonal spreading in our hospital. Unfortu-
nately, a molecular study to confirm the clonal spreading
was not performed at that moment.
Our fourth leading causative pathogen was A. lwoffii
(formerly A. calcoaceticus var. lwoffii) which is well rec-
ognized as skin, oral and perineal flora [21]. Bacteremia
caused by this pathogen is mostly related to catheter-
related infection and has a good prognosis [21].
B. pseudomallei, the causative agent of melioidosis was
noted as the fifth leading causative pathogen in our
study. This pathogen is widely distributed in soil and
rice paddies and considered an endemic pathogen in
Southeast Asia especially Thailand.
Prevalence of multi-drug resistance among our A.
baumannii isolates was considerably higher when compar-
ing to other pathogens. Although several studies reported
the excellent susceptibility of TIG against MDR-AB
[22,23], but less than one-third of our multidrug-resistant
A. baumannii (MDR-AB) isolates were susceptible to TIG.
According to the susceptibility results, CST appeared to be
the most optimal antimicrobial agent for treatment of
MDR-AB-causing bacteremia in our hospital. Despite the
high prevalence of MDR-AB, only 5% of P. aeruginosa iso-
lates were multi-drug resistant; however, 80% of these
MDR-PA were susceptible to CST.
CAZ and SXT given alone or in combination have
been recommended as a treatment of choice for S.
maltophilia infection [8]. According to our susceptibility
result, however, SXT appeared to be the most promising
therapeutic option.
Both CAZ and IMP showed 100% activity against B.
pseudomallei while only 75% of B. pseudomallei were sus-
ceptible to SXT. Currently, CAZ- or IMP- based regimen
is the preferable intravenous intensive-phase therapy while
SXT is documented as the best oral eradication-phase
therapy regardless the susceptibility result [24].
The ID-mortality in our study was quiet high, ranging
from 17.4% in the uncommon NFGNB group to 63.0%
in the A. baumannii group. The US surveillance study
(SCOPE) reported only 34.0% crude mortality among
patients with A. baumannii bacteremia [4] while another
study conducted in Spain found that the ID-mortality
among patients with NFGNB bacteremia was only 12.5%
[7]. Nonetheless, both studies were conducted in the
past decade which a prevalence of multidrug resistance
was relatively low. We believe that the high ID-mortality
was the result of the high prevalence of multidrug-
resistance among A. baumannii pathogen. This hypoth-
esis has been proved in previous publications [25,26].
In contrast to the common NFGNB, the ID-mortality
in the uncommon NFGNB group was relatively low.
Due to the high virulence of A. baumannii and P.
aeruginosa infection, it would be very useful if physi-
cians could distinguish patients who are at risk for A.
baumannii and P. aeruginosa pathogens from those
who are at risk for uncommon NFGNB. Given this rea-
son, we performed additional analysis to identify factors
associated with the uncommon NFGNB bacteremia.
This would have important implications for selecting
empiric antibiotic therapy when the identification and
susceptibility results are not yet available. For the high
risk patients, polymyxin E is probably the most promis-
ing choice in our institution.
Our study has several strengths compared with previ-
ous studies. First, while most studies focused only on P.
aeruginosa and/or A. baumannii [9,20,27] we investi-
gated all species of NFGNB. Second, our study included
only patients with true bacteremia (patients who had at
least one positive blood cultures for NFGNB and met
the definition of SIRS within 24 hours of the onset of
bacteremia), whereas other studies failed to distinguish
true bacteremia from contamination [7]. Third, and most
importantly, we also performed the molecular identifica-
tion on all NFGNB isolates that could not be identified by
conventional method. Without this, we would not be able
to identify at least 20% of NFGNB isolates. We believed
that our study provides thorough and accurate informa-
tion on the distribution of causative pathogens.
Our study, however, has several potential limitations.
First, many variables were obtained by chart-review.
Therefore, informative bias and incompleteness of data
may be issues. Additionally, some isolates could not be
definitely identified to the species level by the 16S rDNA
Table 4 Factors that independently associated with bacteremia caused by uncommon NFGNB (multivariable analysis)
Uncommon NFGNB Unadjusted OR [95% CI] Adjusted OR [95% CI] Multivariate
P-value
Male sex 0.31 [0.17-0.56] 0.28 [0.14-0.53] <0.001
Previous exposure to aminoglycosides 0.27 [0.08-0.77] 0.23 [0.06-0.8] 0.01
Previous exposure to vancomycin 1.83 [0.72-4.62] 3.88 [1.35-11.1] 0.02
Hospital-acquired infection 0.36 [0.18-0.72] 0.23 [0.11-0.51] <0.001
Primary bacteremia 3.66 [1.79-7.56] 6.43 [2.89-14.2] <0.001
Catheter-related infection 2.27 [0.83-6.39] 4.48 [1.54-13.06] <0.001
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gene sequencing technique. This may be the result of
the limitation of sequence database or sequence identity
of some closely related species. Moreover, some clinical
specimens were insufficient for molecular study. These
may result in misclassification although it is unlikely this
would result in differential bias.
Conclusions
The epidemiology of NFGNB bacteremia in our hospital
was slightly different from previous studies. Our study
found the relatively higher ID-mortality among patients
with A. baumannii and P. aeruginosa bacteremia. The in-
dependent factors associated with uncommon NFGNB
bacteremia documented in this study can be used to dis-
tinguish the low risk patients from the high risk patients
who would need empiric broad-spectrum antibiotics while
waiting for species identification and susceptibility results.
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